580 reports of this reaction
2.2% of all ALISKIREN HEMIFUMARATE reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for ALISKIREN HEMIFUMARATE, manufactured by LXO US Inc.. There are 580 FDA adverse event reports linking ALISKIREN HEMIFUMARATE to HEADACHE. This represents approximately 2.2% of all 26,137 adverse event reports for this drug.
Patients taking ALISKIREN HEMIFUMARATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for ALISKIREN HEMIFUMARATE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for ALISKIREN HEMIFUMARATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 580 FDA reports for ALISKIREN HEMIFUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.2% of all adverse event reports for ALISKIREN HEMIFUMARATE, making it one of the most commonly reported side effect.
If you experience headache while taking ALISKIREN HEMIFUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.